Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Onofrio Antonio Catalano, M.D.

Co-Author

This page shows the publications co-authored by Onofrio Catalano and Mark Vangel.
Connection Strength

3.149
  1. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2022 Feb 17.
    View in: PubMed
    Score: 0.247
  2. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021 09; 125(7):975-982.
    View in: PubMed
    Score: 0.237
  3. PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis. Eur J Nucl Med Mol Imaging. 2021 06; 48(6):1976-1986.
    View in: PubMed
    Score: 0.229
  4. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol. 2021 06; 23(3):456-466.
    View in: PubMed
    Score: 0.229
  5. PET/MRI Radiomics in Rectal Cancer: a Pilot Study on the Correlation Between PET- and MRI-Derived Image Features with a Clinical Interpretation. Mol Imaging Biol. 2020 10; 22(5):1438-1445.
    View in: PubMed
    Score: 0.224
  6. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 07; 47(8):1871-1884.
    View in: PubMed
    Score: 0.211
  7. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020 01; 47(1):105-114.
    View in: PubMed
    Score: 0.208
  8. Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2019 Oct; 46(11):2260-2269.
    View in: PubMed
    Score: 0.207
  9. Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2147-2154.
    View in: PubMed
    Score: 0.192
  10. Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nucl Med Mol Imaging. 2018; 8(1):62-69.
    View in: PubMed
    Score: 0.187
  11. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Int J Oncol. 2017 Jul; 51(1):281-288.
    View in: PubMed
    Score: 0.178
  12. Colorectal cancer staging: comparison of whole-body PET/CT and PET/MR. Abdom Radiol (NY). 2017 04; 42(4):1141-1151.
    View in: PubMed
    Score: 0.176
  13. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer. 2017 Mar 28; 116(7):893-902.
    View in: PubMed
    Score: 0.175
  14. Evaluation of Quantitative PET/MR Enterography Biomarkers for Discrimination of Inflammatory Strictures from Fibrotic Strictures in Crohn Disease. Radiology. 2016 Mar; 278(3):792-800.
    View in: PubMed
    Score: 0.159
  15. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer. 2015 Apr 28; 112(9):1452-60.
    View in: PubMed
    Score: 0.154
  16. Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study. Radiology. 2013 Dec; 269(3):857-69.
    View in: PubMed
    Score: 0.139
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.